Even though pCR rates were higher in patients with PD-L1 positive compared to PD-L1-negative tumours (54.3% versus 30.0%, respectively, p = 0.048), PD-L1 expression did not predict for response to durvalumab [20]. Here, CD274 is linked to neoplasm.